Bsx stock forecast 2025 reflects strong backlog conversion

BSX stock forecast 2025 reflects strong backlog conversion rates and an expanding geographic footprint in Asia-Pacific. Currency-neutral sales growth targets remain robust, countering FX headwinds seen in On September 30, 2025, Boston Scientific Corporation presented at MEDevice Boston, featuring insights from Ann Roy, Vice President of Health Economics and Market Access, and Liza Davis, Vice President of R&D for Endoscopy, at the Boston Convention & Exhibition Center. US FDA slaps new requirements for Indonesia's shrimp and spices after radioactive contamination Technical charts for BSX stock forecast 2025 show upward momentum, with possible resistance near the $70 mark. Institutional buyers continue to accumulate positions, signaling confidence in long-term earnings growth trajectories.